Treatment outcome of GDP regimen for patients with refractory or relapsed adult T-cell leukemia-lymphoma
نویسندگان
چکیده
منابع مشابه
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
On July 3, 2014, the FDA granted accelerated approval for belinostat (Beleodaq; Spectrum Pharmaceuticals, Inc.), a histone deacetylase inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). A single-arm, open-label, multicenter, international trial in the indicated patient population was submitted in support of the application. Belinostat was adm...
متن کاملcorrection: gdp versus eshap regimen in relapsed and/or refractory hodgkin lymphoma: a comparison study
#no abstract#
متن کاملgdp versus eshap regimen in relapsed and/or refractory hodgkin lymphoma: a comparison study.
despite multiple published studies reporting result of salvage regimens for relapsed and refractory hodgkin's lymphoma, there are no comparisons of different combinations.a total of 44 patients identified with refractory or relapsed hodgkin's lymphoma were considered eligible for this study. the patients were randomly divided into two groups of 22, one of which were treated with gdp regimen (ge...
متن کاملGemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
T-cell lymphoma (TCL) is resistant to conventional chemotherapy. We retrospectively evaluated the therapeutic efficiency and toxicity of gemcitabine, navelbine, and doxorubicin (GND) in patients with refractory or relapsed TCL. From 2002 to 2012, 69 patients with refractory or relapsed TCL received GND treatment in our hospital. The treatment protocol comprised gemcitabine (800 mg/m(2), group 1...
متن کاملA phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma
Adult T-cell leukemia/lymphoma (ATL) is a malignancy of peripheral T-lymphocytes with a poor prognosis. This multicenter, two-stage, single-arm, phase II study assessed the efficacy and safety of bortezomib in patients with relapsed/refractory ATL who received at least one regimen of chemotherapy. The primary endpoint was the best overall response rate (ORR), and secondary endpoints included sa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2015
ISSN: 0923-7534
DOI: 10.1093/annonc/mdv472.188